Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Robust estimation of quantitative perfusion from multi-phase pseudo-continuous arterial spin labeling.

Magnetic resonance in medicine·2019
Same author

High Levels of Patient Satisfaction in Joint Uro-oncology Clinics to Assist Patient Choice in Early Prostate Cancer and Muscle-invasive Bladder Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2018
Same author

Corrigendum to "Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits" [Clin Oncol 27 (7) (2015) 420-426].

Clinical oncology (Royal College of Radiologists (Great Britain))·2017
Same author

The National Institute for Health and Care Excellence (NICE) Guidance on Bladder Cancer; a Step in the Right Direction?

Clinical oncology (Royal College of Radiologists (Great Britain))·2017
Same author

Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2015

Related Experiment Video

Updated: Apr 16, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits.

K J Ray1, N R Sibson1, A E Kiltie1

  • 1Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|March 11, 2015
PubMed
Summary

Hypofractionated radiotherapy, delivering higher doses over fewer sessions, shows promise for breast and prostate cancer treatment. Research explores its benefits, mathematical conversions, and clinical trial outcomes for improved patient results.

Keywords:
breast cancerclinical trialshypofractionationprostate cancerradiotherapyα/βratio

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

47.7K

Related Experiment Videos

Last Updated: Apr 16, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

47.7K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background:

  • Breast and prostate cancers are leading UK diagnoses, commonly treated with radiotherapy.
  • In vitro studies suggest unique tumor properties favor hypofractionation for an improved therapeutic index.
  • Clinical trials investigate hypofractionated radiotherapy to enhance patient outcomes.

Purpose of the Study:

  • To describe hypofractionation in radiotherapy.
  • To provide mathematical methods for converting between conventional and hypofractionated schedules.
  • To explain the rationale for hypofractionation in breast and prostate cancer treatment.

Main Methods:

  • Review of hypofractionation principles and mathematical conversions.
  • Summary of key clinical trials on hypofractionated radiotherapy.
  • Analysis of hypofractionation's advantages and limitations.

Main Results:

  • Hypofractionation may offer a better therapeutic index for breast and prostate tumors.
  • Numerous trials have assessed the efficacy of hypofractionated schedules.
  • Results from recent trials are summarized, highlighting potential benefits.

Conclusions:

  • Hypofractionated radiotherapy is a developing treatment strategy for breast and prostate cancers.
  • Understanding the mathematical basis and clinical evidence is crucial.
  • Limitations of hypofractionation require consideration for optimal patient care.